Aurigene Pharmaceutical Services Limited (APSL) is an integrated partner for global pharma companies. It covers the entire value chain for new therapeutics, from drug discovery, clinical research, and development to manufacturing APIs and formulation at commercial scales. It has development laboratories from discovery to clinical phase III for New Chemical and Biological Entities (NCEs/NBEs) and cGMP manufacturing facilities in the UK, Mexico, USA, and India. The technology platforms include cytotoxic APIs, carbohydrates, steroids, PEG derivatives, prostaglandins, peptides, and oligonucleotides. Large molecule discovery services include ADC, MAB, mRNA, CART-T as well as development services in MAB and protein therapeutics.
At our state-of-the-art drug discovery facility for oligonucleotide synthesis, our team accelerates your early drug discovery. With years of experience in small molecules, we can design molecules, overcoming bioavailability issues, and devising a fast-forward approach for your oligo targets across therapeutic areas such as oncology, inflammation, and anti-bacterial, etc.
20+ years of experience in accelerating drug innovation
Highly experienced scientific and scale-up teams
Dedicated manufacturing setup withpilot and commercial scale capability
Industry-leading expertise in discovery and CMC services
Strong and sustainable Operations
Advocates of long-term partnerships
Flexible services and business model
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.